Biotech News

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

Rocket Pharmaceuticals (RCKT)Rocket PharmaceuticalsFDA / regulatory

FDA confirms pivotal efficacy population of 12 patients, including the first three treated under the modified protocol FDA review of initial safety data supports continued enrollment and dosing under modified protocol FDA confirms established 12-month co-primary endpoints intended to support

Related news

RCKTRocket Pharmaceuticals2026-10-07 13:36 EST

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

ARWRArrowhead Pharmaceuticals2026-10-07 11:30 EST

Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia

ETONEton Pharmaceuticals2026-10-14 10:50 EST

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

RCKTRocket Pharmaceuticals2026-11-12 21:00 EST

Rocket Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Recent Progress

KPTIKaryopharm Therapeutics2026-11-17 12:30 EST

Karyopharm Announces FDA Acceptance of Supplemental New Drug Application for XPOVIO® (selinexor) Plus Ruxolitinib for the Treatment of Patients with Myelofibrosis

BCRXBioCryst Pharmaceuticals2026-10-21 11:00 EST

BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE

EDITEditas Medicine2026-10-08 11:00 EST

Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia

OCGNOcugen2026-09-25 11:02 EST

Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa

ABEOAbeona Therapeutics2026-09-18 11:30 EST

Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)

RAREUltragenyx Pharmaceutical2026-09-17 19:48 EST

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

Rocket Pharmaceuticals

Gene Therapies for Rare Disease Rocket Pharmaceuticals develops gene therapies for rare hematologic and cardiovascular disorders using lentiviral and adeno-associated-virus vectors. Commercial Hematology Franchise KRESLADI is an ex vivo lentiviral gene therapy approved for severe leukocyte adhesion deficiency type I. It represents...

Recent company news

Stock data

Close
2.11 USD
Market cap
315.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States